Method of treating the symptoms of human rhinovirus infection

Details Method of treating the symptoms of human rhinovirus infection Method of treating the symptoms of human rhinovirus infection

1995-10-17

1996-12-03

Bleutge, John C.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

424464, 514562, 514563, 514885, 560 16, 562557, A61K 908, A61K 920, A61K 948

Patent

active

055805779

ABSTRACT:
A method of treating viral infection comprises the step of administering to a patient harboring a disease-inducing virus other than HIV-1, the virus being one for which an intracellular thiol deficit causes or exacerbates expression of viral genetic information by transcription, translation or viral replication, such as human rhinovirus, an amount effective to inhibit transcriptional or translational expression of genetic information or replication of the virus, of an N-(C.sub.1-4)-acylcysteine, such as N-acetyl cysteine, or a pharmaceutically acceptable salt thereof. Prevention of disease symptoms and reduction of their severity results from the foregoing treatment. Combination of N-(C.sub.1-4)-acylcysteine or its salt with another antiviral drug or drug for alleviating symptoms of viral infection provides additional therapeutic benefits.

REFERENCES:
patent: 3184505 (1965-05-01), Martin et al.
patent: 4184885 (1979-04-01), Renoux et al.
patent: 4335210 (1982-06-01), Meister et al.
patent: 4434158 (1984-02-01), Meister et al.
patent: 4438124 (1984-03-01), Meister et al.
patent: 4440788 (1984-04-01), Terayama et al.
patent: 4619934 (1986-10-01), Sunshine et al.
patent: 4647571 (1987-03-01), Meister et al.
patent: 4665082 (1987-05-01), Meister et al.
patent: 4708965 (1987-11-01), Morgan
patent: 4710489 (1987-12-01), Meister
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4744989 (1988-05-01), Payne et al.
patent: 4758551 (1988-07-01), Meister et al.
patent: 4772471 (1988-09-01), VanLerberghe et al.
patent: 4784685 (1988-11-01), Meister
patent: 4789633 (1988-12-01), Huang et al.
patent: 4827016 (1989-05-01), Morgan
patent: 4879370 (1989-11-01), Meister
patent: 4931473 (1990-06-01), Kellener et al.
patent: 4968506 (1990-11-01), Appelgren et al.
patent: 4970236 (1990-11-01), Ziggiotti et al.
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 5080906 (1992-01-01), Carenzi et al.
Passwater, Super Nutrition, Gulfwestern Pocket Books, NY, NY, pp. 154, 155, (1976).
Burton et al, Human Nutrition, 4th ed. McGraw-Hill, pp. 50-53, 60-62, (1988).
West et al, Textbook of Biochemistry, 4th ed. Macmillan, NY, NY, pp. 1143-1147 and 1243-1250.
"Surrogate Endpoints in Evaluating the Effectiveness of Drugs Against HIV Infection and AIDS", Sep. 11-12, 1989, Conference Summary, Robin Weiss and Leah Mazade, editors, The Roundtable for the Development of Drugs and Vaccines Against AIDS, Institute of Medicine, National Academy Press, Washington, DC, 1990.
Ishii et al, Journal of Cellular Physiology, 133:330-336 (1987).
Kosower et al, Nature, 224:117-120 (1969).
Ketterer, Mutation Research, 202:343-361 (1988).
Ziegler, Ann. Rev. Biochem., 54:305-29 (1985).
Orrenius et al, "Regulation of Calcium Compartmentation in the Hepatocyte--A Critical Role of Glutathione", Functions of Glutathione: Biochemical Physiologicl, Toxicological, and Clinical Aspects, Larsson et al eds., Raven Press, NY NY, 1983, pp. 261-271.
Martensson et al, Proc. Natl. Acad. Sci. USA, 86:471-475 (1989).
Droge et al, Immunobiol., 172:151-156 (1986).
Ristow et al, Immunological Investigations, 14:(5)401-414 (1985).
Bannai et al, J. Membrane Biol., 89:1-8 (1986).
Wu et al, Clin. exp. Immunol., 77:7-10 (1989).
Richman et al, The American Journal of Medicine, 85:208-213 (Suppl 2A) (1988).
Moldeus et al, Respiration, 50: Suppl. 1, 31-42 (1986).
Ziment, Respiration, 50: Suppl. 1, 26-30 (1986).
Yunis et al, Respiration, 50: Suppl. 1, 50-55 (1986).
de Quay et al, "Glutathione Depletion in HIV-infected Patients: Role of Cysteine Deficiency and Effect of Oral N-Acetylcysteine", Swiss National Foundation for Scientific Research.
Mitsuya et al, Japan Sci. Soc. Press Utrect, pp. 277-288, (1985).
Moody et al, "Potential therapeutic application autologous CD8+ cells from HIV-infected subjects." IV Int. Conf. AIDS (abstract) Stockholm (1988).
Droge et al, Biol. Chem. Hoppe-Seyler, 369:143-148, (1988).
Eck et al, Biol. Chem. Hoppe-Seyler, 370:109-113, (1989).
Eck et al, Biol. Chem. Hoppe-Seyler, 370:101-108, (1989).
Walker et al, Cellular Immunology, 119:470-475, (1989).
Root-Berstein, Genetic Engineering News, Sep. 1, 1992, pp. 4-6.
Root-Berstein, Genetic Engineering News, Sep. 15, 1992, pp. 4-5.
Staal et al, "Glutathione Deficiency And Human Immunodeficiency Virus Infection," Lancet, 339:909-912, (1992).
Staal et al, "Intracellular Glutathione Levels In T Cell Subsets Decrease In HIV-Infected Individuals," Aids Research And Human Retroviruses, 8(2):305-311, (1992).
Roederer et al, "N-Acetylcysteine: A New Approach To Anti-HIV Therapy," Aids Research And Human Retroviruses, 8(2):209-217, (1992).
Staal et al, "Intracellular Thiols Regulate Activation Of Nuclear Factor .kappa.B and Transcription Of Human Immunodeficiency Virus," Proc. Natl. Acad. Sci. USA, 87:9943-9947, (1990).
Roedere et al, "Cytokine-Stimulated Human Immunodeficiency Virus Replication Is Inhibited by N-acetyl-L-cysteine," Proc. Natl. Acad. Sci. USA, 87:4884-4888, (1990).
Roedere et al, "N-Acetylcysteine Inhibits Latent HIV Expression In Chronically Infected Cells," Aids Research And Human Retroviruses, 7(6):563-567, (1991).
Roederer et al, "The Interrelationship Of TNF, Glutathione, And AIDS," TNF3 (Bassel. Karger, in press pp. 1-15, (1991).
Staal et al, "Glutathione And Immunophenotypes Of T And B Lymphocytes In HIV-Infected Individuals," Annals N.Y. Acad. Sci., pp. 1-10, (1992).
Roederer et al, "CD4 And CD8 T Cells With High Intracellular Glutathione Levels Are Selectively Lost As The HIV Infection Progresses," Intl. Immunol., 3(9):933-937, (1991).
Staal et al, "CD20 Expression Is Increased On B Lymphocytes From HIV-Infected Individuals," (in press), pp. 1-21.
De Quay et al, "Glutathione Depletion In HIV-Infected Patients: Role Of Cysteine Deficiency And Effect Of Oral N-Acetylcysteine," (in press), pp. 1-20.
Roedere et al, "Disregulation Of Leukocyte Glutathione in AIDS," (in press), pp. 1-23.
B. DeJong et al "Augmentation of Chinese Hamster Lymphocyte Stimulation by Cysteine" Jour. of Imm. Methods, 68 (1984) 55-60.
Ohmori et al "Mechanism of Augmentation of the Antibody Response etc." J. Exp. Med, vol. 155, May 1982, pp. 1277-1290.
Miller et al "Clinical Safety of High Oral Doses of Acetylcysteine" Seminars in Oncology, vol. 10, No. 1, Suppl. 1 (Mar.) 1983, 76-85.
Kalebic et al., Proc. Natl. Acad Sci, vol. 88 pp. 986-990, Feb. 1991 "Suppression of Human Immunodeficiency Virus Expression in Chronically etc."
Buhl et al "Systemic Glutathione Deficiency in Sympton-Free etc." The Lancet, Dec. 2, 1989, 1294-1298.
Zimmerman et al. "The Role of Oxidant Injury in Tumor Cell Sensitivity etc." The Journal of Immunology, vol. 142, 1405-1409 Feb. 15, 1989.
Fidelus et al. "Modulation of Intracellular Glutathione Concentrations etc." Experimental Cell Research 170 (1987) pp. 269-275.
Fidelus et al. "Glutathione and Lymphocyte Activation: etc." Immunology, 1987 61, pp. 503-508.
Fidelus et al. "Enhancement of Intracellular Glutathione Promotes etc." Cellular Immunology 97, 155-163 (1986).
Mitsuya et al "3'-Azido-3'-deoxythymidine etc." Proc. Natl. Acad. Sci. vol. 82, pp. 7096-7100, Oct. 1985.

Affiliated with

Also associated with

Rating

Method of treating the symptoms of human rhinovirus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating the symptoms of human rhinovirus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating the symptoms of human rhinovirus infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-783400